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Abstract Vosaroxin is a first-in-class anticancer quinolone
derivative that targets topoisomerase II and induces site-
selective double-strand breaks in DNA, leading to tumor
cell apoptosis. Vosaroxin has chemical and pharmacologic
characteristics distinct from other topoisomerase II inhibi-
tors due to its quinolone scaffold. The efficacy and safety
of vosaroxin in combination with cytarabine were evalu-
ated in patients with relapsed/refractory acute myeloid
leukemia (AML) in a phase III, randomized, multicenter,
double-blind, placebo-controlled study (VALOR). In this
study, the addition of vosaroxin produced a 1.4-month
improvement in median overall survival (OS; 7.5 months
with vosaroxin/cytarabine vs. 6.1 months with
placebo/cytarabine; hazard ratio [HR] 0.87, 95 % confi-
dence interval [CI] 0.73-1.02; unstratified log-rank
p ¼ 0.061; stratified log-rank p ¼0.024), with the greatest
OS benefit observed in patients C60 years of age (7.1 vs.
5.0 months; HR 0.75, 95 % CI 0.62-0.92; p ¼0.003) and
patients with early relapse (6.7 vs. 5.2 months; HR 0.77,
95 % CI 0.59-1.00; p ¼ 0.039), two AML patient groups
that typically have poor prognosis. Here we review the
chemical and pharmacologic properties of vosaroxin, how
these properties are distinct from those of currently avail-
able topoisomerase II inhibitors, how they may contribute
to the efficacy and safety profile observed in the VALOR
trial, and the status of clinical development of vosaroxin
for treatment of AML.
Key Points
Vosaroxin is a first-in-class anticancer quinolone
derivative that inhibits topoisomerase II causing
tumor cell apoptosis.
Due to the stability of its quinolone core, vosaroxin
is not associated with significant formation of toxic
metabolites, free radicals, or reactive oxygen species,
which are associated with off-target organ damage
and cardiotoxicity.
Vosaroxin is not a substrate for the P-glycoprotein
efflux pump, and vosaroxin activity is maintained in
cells with p53 deletion thus evading two common
mechanisms of drug resistance.
In the phase III VALOR trial, the addition of
vosaroxin to cytarabine was shown to provide
clinical benefit to some patients with relapsed or
refractory AML, particularly older patients and those
with early relapsed disease.
The unique chemical and pharmacologic
characteristics of vosaroxin may contribute to the
efficacy and safety profile observed in the phase III
VALOR trial.
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Vosaroxin is an anticancer quinolone derivative (AQD) in
development for patients with relapsed/refractory acute
myeloid leukemia (R/R AML). It is the first in a novel class
of antineoplastic agents (non-antibacterial fluoroquinolone
derivatives) recognized by the United States Adopted
Names Council [1]. Vosaroxin induces replication-depen-
dent DNA damage by intercalating DNA and inhibiting
topoisomerase II, which induces cancer cell apoptosis [2].
This review describes the chemical and pharmacologic
properties of vosaroxin, highlights the differences as
compared with currently approved topoisomerase II inhi-
bitors, and summarizes the clinical development of vosar-
oxin for AML.
2 Vosaroxin Discovery
Nalidixic acid was the first quinolone synthesized, in the
early 1960s, demonstrating antibacterial properties [3].
Antibacterial quinolones induce DNA damage by inhibit-
ing bacterial topoisomerases, DNA gyrase and topoiso-
merase IV, which are functional analogs of mammalian
topoisomerase II [4, 5]. The homology between mam-
malian and bacterial topoisomerases, and the fact that
mammalian topoisomerase II is a well-established target of
antineoplastic drugs [6–9], provided the rationale for
screening and identification of AQDs that selectively target
mammalian topoisomerase II [6–11]. Although eukaryotic
DNA topoisomerase II and bacterial homologs share
regions with[50 % amino acid sequence homology and a
conserved three-domain tertiary structure, there are sub-
stantial differences in the enzymatic reaction mechanism
and quaternary structure of the eukaryotic and bacterial
enzymes [12, 13]. These differences may underlie the
specificity demonstrated by antibiotics that are potent
inhibitors of bacterial topoisomerases but are effective only
at very high, clinically irrelevant concentrations against the
eukaryotic homologs. Conversely, this distinction allows
selection of inhibitors specific for human DNA topoiso-
merase II [14].
Vosaroxin (SNS-595, voreloxin) was selected from a
mouse P388 leukemia cell-based screen that examined
structure-activity relationships of novel quinolone deriva-
tives to identify a potent antineoplastic agent that prefer-
entially targets mammalian topoisomerase II [11]. The
selectivity of vosaroxin for mammalian topoisomerase II
was substantiated by the absence of antimicrobial activity
in vitro against Candida albicans, Enterococcus faecalis,
Escherichia coli, Pseudomonas aeruginosa, and Staphylo-
coccus aureus at vosaroxin concentrations approximately
20-fold higher than the average maximum clinical
concentration (data on file, Sunesis Pharmaceuticals, South
San Francisco, CA, USA).
3 Interaction of Vosaroxin with DNA
and the Topoisomerase II Cleavage Complex
Topoisomerase II is essential for the survival of eukaryotic
cells [8, 9, 12, 15, 16]. The enzyme maintains DNA
topology throughout replication, supporting correct chro-
mosome condensation, decondensation, and segregation.
Topoisomerase II performs these functions via a chore-
ographed sequential decatenation/concatenation of the
DNA helix, catalyzing formation of a double-strand break
in DNA and passage of an intact DNA strand through the
cleavage site; the enzymatic sequence is completed by
religation of the double-strand DNA break [6–9, 15, 16].
Inhibitors of topoisomerase II classified as ‘‘topoisomerase
poisons’’ act by stabilizing the covalent topoisomerase
II/DNA complex (cleavage complex) after the DNA has
been cleaved. This results in the conversion of transient
DNA double-strand breaks into permanent lesions and
subsequently causes cell-cycle arrest and apoptosis in
replicating cells [7, 8]. Examples of topoisomerase II poi-
sons are the anthracyclines doxorubicin, daunorubicin, and
idarubicin, the anthracenedione mitoxantrone, and the
epipodophyllotoxin etoposide.
Both topoisomerase II poisoning and DNA intercalation
contribute to vosaroxin activity [2]. Vosaroxin acts as a
topoisomerase II poison, stabilizing cleavage complexes
formed by topoisomerase II a and II b isoforms, and
resulting in an accumulation of DNA double-strand breaks,
perhaps via prevention of DNA ligation [2, 17]. Similar to
doxorubicin, daunorubicin, idarubicin, and mitoxantrone
(and unlike etoposide), vosaroxin directly intercalates
DNA [6–8, 18]. As with other intercalating topoisomerase
II inhibitors, higher levels of DNA breaks are seen at lower
vosaroxin concentrations; at concentrations above 1.0 lM
vosaroxin, a decrease in DNA breaks is observed [2, 14];
this finding may be due to catalytic inhibition or restricted
access of topoisomerase II as intercalation into DNA
increases. Notably, etoposide, mitoxantrone, and the
anthracyclines also exhibit non-topoisomerase II-depen-
dent DNA damage due to metabolic activation and oxida-
tive stress [19–27]. In contrast, these mechanisms do not
contribute significantly to vosaroxin activity, which
appears to be mediated exclusively through DNA interca-
lation and topoisomerase II inhibition [2, 31, 37].
Vosaroxin targets actively replicating cells; the extent of
DNA damage is cell-cycle dependent, with dose-dependent
damage observed mainly in late G2/M and S cell-cycle
phases [17]. This DNA damage induces G2/M arrest and
S-phase lag [2, 17, 28]. Maximum generation of double-
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strand breaks and cytotoxic activity occurs in G2/M for
both vosaroxin and the anthracyclines, consistent with peak
topoisomerase II expression at G2 [17]. Conversely,
vosaroxin induces a different DNA damage pattern in
S-phase as compared with the anthracycline doxorubicin.
Unlike with doxorubicin, double-strand breaks were not
detected in S-phase with vosaroxin. Vosaroxin appears to
prolong S-phase possibly due to torsional stress from
cleavage complexes near sites of DNA replication that
cause the replication fork to stall [17].
Topoisomerase II is a metalloenzyme with two metal
ion-binding sites coordinated through protein catalytic
pockets. The catalytic activity of topoisomerase II is
mediated by magnesium ions (Mg2?), which facilitate
DNA bending and subsequent cleavage [29]. Quinolones
and quinolone derivatives also act as sequestering ligands,
with binding sites that can chelate divalent metal cations
such as Mg2? in 1:1 or 1:2 (metal:quinolone) stoichiome-
try. X-ray crystallography has revealed that two Mg2? ions
mediate the interaction between quinolones and topoiso-
merase IV [30], and coordination of Mg2? has been shown
to play a critical role in quinolone-based molecule activity
[30–32]. In vitro studies show that, unlike with the
anthracyclines (14), Mg2? coordination is required for
vosaroxin activity, similar to its quinolone predecessors
[2].
The functional differences observed between vosaroxin
and classic topoisomerase II inhibitors result from the
unique vosaroxin scaffold. The resulting three-dimensional
structure of vosaroxin is distinct from those of other
topoisomerase II inhibitors; quinolones have a ‘‘wedge’’
shape, in contrast to the planar form of anthracyclines,
supporting a mechanistically distinct interaction with DNA
(Fig. 1) [30, 33, 34]. Vosaroxin causes site-selective DNA
damage in G/C-rich sequences [2], which is characteristic
of quinolone-induced DNA damage. In contrast, anthra-
cyclines favor 30 A at the cleavage site [2, 35, 36].
4 The Quinolone Scaffold of Vosaroxin is
Chemically Stable and Minimally Metabolized
Vosaroxin’s quinolone scaffold confers chemical and
pharmacologic characteristics distinct from classic topoi-
somerase II poisons used in AML treatment. Compared
with currently approved topoisomerase II inhibitors,
vosaroxin is minimally metabolized because of its
stable quinolone core. In vitro studies in human micro-
somes demonstrated that [97 % of vosaroxin remained
unchanged after incubating for up to 60 min [37]. Con-
sistent with in vitro data, unchanged vosaroxin was the
major species identified in plasma, urine, and bile follow-
ing intravenous (IV) administration of [14C]-vosaroxin to
rats [37]. N-Desmethylvosaroxin, an equipotent metabolite
of vosaroxin, was the sole metabolite (M4) identified in the
plasma of rats, monkeys, and humans, accounting for B3 %
of the total vosaroxin exposure (data on file, Sunesis
Pharmaceuticals, South San Francisco, CA, USA) [37].
Vosaroxin is not associated with significant formation
of free radicals or reactive oxygen species (ROS) [2, 37],
A B
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Fig. 1 Distinct chemical structures of topoisomerase II inhibitors.
The quinolone core is circled on vosaroxin (a) and ciprofloxacin
(b) to emphasize the differences from other classes of topoisomerase
II inhibitors: c anthracenedione (mitoxantrone); d epipodophyllotoxin
(etoposide); and e anthracycline (doxorubicin)
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whereas anthracyclines mediate formation of ROS in the
forms of hydrogen peroxide (H2O2) and superoxide
radical anion (O2
-) via multiple mechanisms. One well-
characterized mechanism of anthracycline-mediated ROS
formation involves Fe3? complexation and redox cycling
[31, 38–40]. The interaction with endogenous metal ions,
including magnesium and iron, is fundamental to the
mechanism of action of quinolone- and anthracycline-
based topoisomerase II inhibitors. Iron complexes can
lead to ROS formation via a trivalent, Fe3? complexa-
tion. Vosaroxin and doxorubicin bind Fe3? with com-
parable strength; however, vosaroxin forms a
stable complex with Fe3? at a 1:3 (metal:vosaroxin)
stoichiometry [Fe(vosaroxin)3], where all the reactive
sites on Fe3? are occupied, whereas doxorubicin binds at
a 1:1 and 2:1 (metal:doxorubicin) stoichiometry, leaving
exposed iron-reactive sites (Fig. 2) [31, 41, 42]. At
physiologic pH, doxorubicin forms a mixture of labile
protonated ligand species; in contrast, vosaroxin pre-
dominantly exists as [Fe(vosaroxin)3], a more thermo-
dynamically stable species where the Fe3? ion is
coordinated to six O-atoms of the three vosaroxin
ligands, leaving no unoccupied iron orbital (Fig. 3) [31].
Therefore, the vosaroxin-iron complexes do not support
production of ROS, because the fully occupied iron
coordination geometry does not permit free radical for-
mation. This iron coordination geometry and the minimal
metabolism of vosaroxin are consistent with experiments
Fig. 2 Fe3? complexes formed by vosaroxin and doxorubicin. a 1:3 (Fe3?:vosaroxin) complex, b 1:1, and c 2:1 (Fe3?:doxorubicin) complex
Images are based on Kara et al. 1991 [41] and Drechsel et al. 2001 [42]
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in colorectal cancer cells showing limited ROS with
vosaroxin versus substantial ROS with doxorubicin [2].
Anthracyclines concentrate in the mitochondria of car-
diac cells, where the production of ROS and other toxic
metabolites has been implicated in cumulative cardiotoxi-
city [38–40, 43]. The minimal formation of ROS and other
toxic metabolites may limit vosaroxin off-target car-
diotoxicity. In the placebo-controlled VALOR study, there
was no significant difference in cardiac adverse events
(AEs) between patients treated with vosaroxin plus
cytarabine and those treated with cytarabine alone [44].
Vosaroxin may be a viable alternative for AML patients at
risk of anthracycline-mediated cardiotoxicity because of
prior exposure or co-morbidities.
5 Preclinical Evidence of Vosaroxin
Antineoplastic Activity
Vosaroxin exhibits potent in vitro activity in cancer cell
lines from diverse tissue origins. In 19 solid tumor and
hematologic cancer cell lines, the mean half-maximal
inhibitory concentration was 345 nM (range 40-1155
nM) [33, 45]. Vosaroxin demonstrated comparable or
greater in vivo cytotoxicity compared with etoposide,
doxorubicin, irinotecan, cisplatin, paclitaxel, and 5-fluo-
rouracil in a wide range of human tumors (Table 1). In
hematologic cancer models, vosaroxin demonstrated
increased tumor growth inhibition compared with etopo-
side and doxorubicin. Notably, radiolabeling experiments
in mice indicate that vosaroxin crosses the blood–brain
barrier (manuscript in preparation); although brain tissues
showed that tissue:plasma ratios were B1.5, levels of
radioactivity in brain indicated the presence of vosaroxin
at concentrations associated with anticancer activity
in vitro [33, 45]. In contrast, anthracyclines and the
anthracenedione mitoxantrone do not cross the blood–
brain barrier [46, 47].
Drug efflux by P-glycoprotein 1 efflux transporter (P-gp)
is a common drug-resistance pathway in human cancers;
unlike etoposide and the anthracyclines/anthracenediones,
vosaroxin is not a substrate for P-gp [33, 48]. Vosaroxin
has demonstrated activity in drug-resistant xenograft
models SBC-3/ADM (doxorubicin resistance), SBD-3/ETP
(etoposide resistance), and MES-SA/Dx5 (multidrug
resistance) (Fig. 4) [33]. These tumor models overexpress
P-gp, and SBC-3/ADM and SBD-3/ETP also have reduced
expression levels of topoisomerase II. In the MES-SA/Dx5
xenograft model, vosaroxin has been shown to inhibit
tumor proliferation by 87 %, compared with only 10 %
inhibition by doxorubicin (Fig. 4a) [33].
Notably, the activity of vosaroxin is maintained in cells
with p53 deletion [28, 49]. Deletions and mutations in the
p53 gene are common in relapsed and treatment-related
AML. Correspondingly, p53 alterations are found fre-
quently in AML patients with complex karyotype and in
older patients; these patients often experience chemother-
apy resistance and poor outcomes [50]. The ability of
vosaroxin to evade two common resistance mechanisms
associated with other topoisomerase inhibitors (p53 alter-
ations, P-gp upregulation) may contribute to the complete
remissions observed in vosaroxin-treated patients with
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Fig. 3 Speciation plots for solutions of vosaroxin (a) or doxorubicin
(b) with Fe3? as a function of pH. At physiological pH 7.4 (vertical
line), the predominant Fe3?:vosaroxin species is one Fe3? coordi-
nated by three vosaroxin ligands (FeL3). For doxorubicin, the
predominant species at pH 7.4 is the noncoordinated, charged
doxorubicin ligand (LH3) [31]
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6 Vosaroxin Clinical Development in Acute
Myeloid Leukemia (AML)
The activity of vosaroxin in human leukemic cell lines and
hematologic xenograft models provided the rationale for
clinical study of vosaroxin in patients with hematologic
malignancies. Myelosuppression was observed in preclin-
ical toxicology studies (data on file, Sunesis Pharmaceuti-
cals, South San Francisco, CA, USA) and was dose
limiting in early clinical studies in solid tumors [52]. A
phase Ib dose escalation/pharmacokinetic (PK) study was
conducted in patients with advanced hematologic malig-
nancies (N ¼ 73; median age 65 years) to evaluate dosing
and tolerability [53]. Grade 3 stomatitis was dose limiting
for weekly (days 1, 8, 15) and twice-weekly (days 1, 4, 8,
11) regimens (28-day cycle), resulting in maximum toler-
ated doses of 72 and 40 mg/m2, respectively. In this study,
PK was linear over the dose range of 9–90 mg/m2. Mean
volume of distribution was 119 L, and mean half-life was
approximately 25 h. Mean total body clearance was
approximately 4 L/h and independent of age, sex, body
weight, and body surface area. During biweekly dosing,
limited drug accumulation was observed (average 1.2-
fold), with no evidence of induction or inhibition of
vosaroxin metabolism with repeated dosing.
In two phase II trials, vosaroxin demonstrated clinical
activity in patients with AML. In the first study, three
treatment schedules of single-agent vosaroxin were evalu-
ated in an open-label, multicenter study in patients
C60 years of age with newly diagnosed, poor-risk AML
[54]. In addition, patients were required to have one or more
of the following adverse prognostic factors: age C70 years,
an antecedent hematologic disorder, Eastern Cooperative
Oncology Group performance status of 2, or intermediate or
unfavorable karyotype [defined as t(8;21)(q22;q22);
inv(16)(p13;q22) or t(16;16)(p13;q22); or t(15;17)
(q22;q12) and variants]. The primary objective of the study
was to evaluate the combined complete remission (CR) rate
(CR ? CR with incomplete platelet recovery [CRp]) of
vosaroxin in these patients. A total of 113 patients were
enrolled and treated (29 patients in schedule A [72 mg/m2
days 1, 8, and 15], 35 patients in schedule B [72 mg/m2 days
1 and 8], and 49 patients in schedule C [29 patients at
72 mg/m2 days 1 and 4 and 20 patients at 90 mg/m2 days 1
and 4]). In the overall population, 36 patients (32 %)
achieved CR/CRp (33 with CR and 3 with CRp), with a
median overall survival (OS) of 7.0 months. Thirty-day and
60-day mortality rates were 12 and 31 %, respectively.
Grade C3 AEs occurring in C20 % of patients were
thrombocytopenia (59 %), febrile neutropenia (50 %),
anemia (49 %), neutropenia (29 %), aggregate sepsis (39 %;
aggregate of 32 preferred terms including sepsis, bac-
teremia, fungemia, and viremia), aggregate pneumonia (30
%; aggregate of ten preferred terms), hypokalemia (25 %),
Table 1 Analysis of percent growth inhibition of tumor xenograft models following exposure to vosaroxin, cisplatin, etoposide, irinotecan,
doxorubicin, or paclitaxel [33]


















15 mg/kg ND ND 80* 85* 63* 55* 63* 75* 82* 77* 69* –13 51
20 mg/kg ND 96* 85* 85* 71* 63* 82* 84* 88* 83* 65* –8 55*
25 mg/kg 98* ND ND ND ND ND ND ND ND ND ND ND ND
Cisplatin
10 mg/kg ND 3 25 33 52* 33* 13 25* 84* 55 45 40 ND
Etoposide
12 mg/kg 28 3 45 38 14 –1 26* 31* 45* 1 37 –37 30
Irinotecan
100 mg/kg 100* 98* ND 94* 70* 55* 71* 64* 90* 100* 55 ND ND
Doxorubicin
12 mg/kg 50* 57* 44 47 20 26 40* 49* 70* 99* 46 ND ND
Paclitaxel
28 mg/kg ND ND ND 99* 97* 97* 96* 43* 100* 100* 98* ND ND
42 mg/kg 100* 97* ND ND ND ND ND ND ND ND ND ND ND
ND not determined
* Statistically significant difference as evaluated by comparing the mean tumor size of the vehicle-treated groups to drug-treated groups using a
two-tailed Dunnett’s test. P values less than 0.05 were considered significant
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and stomatitis (22 %). Based on efficacy and safety findings,
vosaroxin 72 mg/m2 on days 1 and 4 was recommended for
further study in this population. CR was achieved in 31 % of
patients at this dose and schedule, with a median OS of 7.7
months, and early mortality was lowest with this dose and
schedule (30- and 60-day mortality rates of 7 and 17 %,
respectively).
In a second phase II trial, vosaroxin was evaluated in
combination with cytarabine, based on preclinical evidence
of synergistic cytotoxicity in AML cell lines and primary
AML patient cells, as well as enhanced activity in a normal
mouse bone marrow ablation/repopulation model [28, 45].
Lancet and colleagues evaluated the combination in this
phase Ib/II, open-label, dose-escalation study in patients
with R/R AML, with expansion at the maximum tolerated
dose (MTD) [51]. Patients received vosaroxin (escalating
doses starting at 10 mg/m2) on days 1 and 4 in combination
with cytarabine either as a 24-h continuous intravenous
(CIV) infusion (400 mg/m2/day 9 5 days; schedule A) or
as a 2-h IV infusion (1 g/m2/day 9 5 days; schedule B).
A total of 110 patients were enrolled and 108 received any
treatment. When combined with cytarabine as a 24-h CIV
infusion, the MTD for vosaroxin was determined to be 80
mg/m2 with grade 3 bowel obstruction and stomatitis as
dose-limiting toxicities. When combined with cytarabine as
a 2-h IV infusion, the MTD for vosaroxin was not reached;
the phase II recommended dose for this combination was
the highest vosaroxin dose tested, 90 mg/m2. These doses
were used in the expansion phase. Among all 108 treated
patients, 24 (22 %) achieved a CR. In the efficacy popu-
lation (patients with first-relapsed or primary refractory
disease who received vosaroxin 80-90 mg/m2; n ¼69), the
CR rate was 25 % and median OS was 6.9 months (95 %
confidence interval [CI] 4.3-10.1 months). Thirty-day
mortality was 9.3 % (10/108) among all treated patients
and 2.5 % (2/78) among patients treated at 80-90 mg/m2;
60-day mortality was 14.8 % (16/108) and 9.0 % (7/78),
respectively. Grade C3 non-hematologic AEs occurring in
C15 % of all patients were aggregated sepsis/bacteremia
(34 %; aggregate of 12 preferred terms), aggregated
infections (19 %; aggregate of 23 preferred terms), hypo-
kalemia (26 %), and stomatitis (15 %). PK of vosaroxin in
combination with cytarabine was similar to that observed
when vosaroxin was administered as a single agent, sug-
gesting that coadministration of cytarabine did not alter
vosaroxin PK. These findings supported the initiation of the
pivotal phase III VALOR trial.
VALOR was a randomized, double-blind, placebo-con-
trolled study evaluating vosaroxin (90 mg/m2 IV, days
1 and 4; 70 mg/m2 in subsequent cycles) plus cytarabine (1
g/m2 IV over 2 h, days 1-5) versus placebo/cytarabine in
711 patients with R/R AML [44]. Eligible patients were
considered fit to receive intensive chemotherapy and must
have already tolerated induction chemotherapy with an
anthracycline (or anthracenedione) plus cytarabine.
Patients were stratified at randomization by age (\60 or
C60 years), disease status (refractory, early relapse, late
relapse), and region (USA, outside of USA). In this study,
median OS was 7.5 months (95 % CI 6.4-8.5 months) for
vosaroxin/cytarabine-treated patients and 6.1 months
(95 % CI 5.2-7.1 months) for placebo/cytarabine-treated
patients (hazard ratio [HR] 0.87, 95 % CI 0.73-1.02;
2-sided unstratified log-rank p ¼ 0.061; 2-sided stratified
log-rank p ¼ 0.024). In predefined subgroup analyses, the
addition of vosaroxin produced the greatest OS benefit in
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Fig. 4 Vosaroxin demonstrates potent anticancer activity in mul-
tidrug-resistant human tumor xenograft models. a MES-SA/Dx5.
b SBC-3/ETP. All agents were administered intravenously using the
schedules and doses indicated in the figure. Inhibition rate (IR)
represents (1 - average tumor weight/average tumor weight control)
9 100 as determined on day 35 after initial treatment. IR values
marked with asterisk are statistically significantly different from those
in the vehicle-treated group. Each schedule and agent had its own
vehicle control group; only the vosaroxin vehicle group is shown.
Error bars indicate one standard deviation. CDDP cisplatin, DOX
doxorubicin, IRN irinotecan [33]
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with placebo/cytarabine; HR 0.75, 95 % CI 0.62-0.92; p ¼
0.003) and in those with early relapse (OS 6.7 vs. 5.2
months; HR 0.77, 95 % CI 0.59-1.00; p ¼ 0.039). Overall,
adding vosaroxin nearly doubled the CR rate (30 vs. 16 %;
p ¼ 0.0001). Similar 30-day (8 vs. 7 %) and 60-day (20 vs.
19 %) all-cause mortality rates were observed between
treatment arms [44].
The safety profile of vosaroxin is consistent with non-
clinical toxicology observations. In VALOR, grade C3 AEs
were primarily related to gastrointestinal events, myelosup-
pression, and infection [44]. The most common grade C3
events (experienced by C10 % of patients treated with
vosaroxin/cytarabine) were febrile neutropenia (47 % with
vosaroxin/cytarabine vs. 34 % with placebo/cytarabine),
thrombocytopenia (24 vs. 25 %), anemia (22 vs. 23 %),
neutropenia (19 vs. 14 %), hypokalemia (15 vs. 6 %),
pneumonia (11 vs. 8 %), stomatitis (16 vs. 3 %), sepsis (12
vs. 5 %), and bacteremia (12 vs. 5 %). Serious AEs were
more frequent in the vosaroxin arm: febrile neutropenia
(11.3 vs. 7.4 % with placebo/cytarabine), sepsis (8.7 vs.
4.3 %), pneumonia (7.6 vs. 4.9 %), bacteremia (8.5 vs. 2.9
%), and stomatitis (3.4 vs. 1.4 %) [55]. Overall, the primary
toxicities of vosaroxin are similar to those observed with
many antineoplastic cytotoxic drugs. However, cardiac,
pulmonary, renal, and hepatic AEs were comparable
between arms, and no clinical evidence was seen with
vosaroxin for such off-target end-organ toxicities, suggest-
ing a possible association with the stability of vosaroxin’s
quinolone core and minimal production of toxic metabolites.
In the clinical setting, quinolone antibiotics have been
associated with nausea, diarrhea, headache, and dizziness.
Rarely, severe AEs such as QTc interval prolongation,
tendonitis/tendon rupture, disturbances in glucose home-
ostasis, crystalluria, interstitial nephritis, acute renal fail-
ure, seizures, and class-specific phototoxicity have been
reported [56]. The incidence of these toxicities in the
VALOR trial was evaluated because vosaroxin is a qui-
nolone derivative; in general, similar frequencies were
observed between treatment arms.
Additionally, interim data from a phase II, multicenter,
randomized, open-label study (LI-1) using the ‘‘Pick a
Winner’’ design were reported for newly diagnosed patients
aged C60 years for whom intensive therapy was not suit-
able [57]. Two vosaroxin-based regimens were compared
with low-dose cytarabine (LDAC): (a) single-agent vosar-
oxin (72 mg/m2 IV days 1 and 4, up to four cycles) versus
LDAC (20 mg subcutaneously twice daily, days 1-10 for at
least four cycles); and (b) vosaroxin plus LDAC versus
LDAC. Selection of the vosaroxin dose (72 mg/m2 IV days 1
and 4, up to four cycles) was based on the efficacy and safety
results for single-agent vosaroxin in newly diagnosed older
patients in the phase II study by Stuart and colleagues [54];
synergy observed in preclinical studies provided the
rationale for the combinationwith LDAC [57]. A total of 104
randomized patients were included in each comparison.
Mean patient age across all arms was 75 years (range 60-91
years). Advanced age was the primary reason patients were
considered not to be candidates for intensive therapy (and
thus were eligible for enrollment), followed by advanced age
with poor performance status. At the first interim analysis,
single-agent vosaroxin did not meet the prespecified hurdle
of 2.5 % absolute improvement in CR rate over LDAC alone
(15 % with vosaroxin vs. 16 % with LDAC), leading to
closure of this study cohort. On the other hand, vosaroxin in
combination with LDAC met the prespecified 2.5 %
improvement in CR rate at the first interim analysis (25 %
with vosaroxin/LDAC vs. 20 % with LDAC). In spite of this
improvement, the data monitoring and ethics committee
recommended closure of this cohort based on preliminary
OS and early mortality data available at the time of the
interim analysis. In the randomization between single-agent
vosaroxin versus LDAC, 30- and 60-daymortality rates were
higher with single-agent vosaroxin than with LDAC
(30-day: 26 vs. 14 %, respectively; 60-day: 38 vs. 20 %) and
OS was shorter in the vosaroxin arm (HR 1.94 [95 % CI
1.26-3.00]). In the vosaroxin/LDAC versus LDAC ran-
domization, 30-day mortality rates were similar between
arms (10 % with vosaroxin/LDAC vs. 11 % with LDAC)
while 60-day rates were higherwith combination therapy (36
vs. 18 % with LDAC); OS was not significantly different
between arms at the interim analysis (HR 1.30 [95 % CI
0.81-2.07]). The investigators concluded that treatment
with vosaroxin was ‘‘more intensive than anticipated’’ and
was unlikely to benefit older AML patients not considered
candidates for intensive therapy. The differences between
findings in the LI-1 study and VALOR are likely related to
differences between the two study populations. The LI-1
study comprised high-risk (advanced age, poor performance
status) newly diagnosed AML patients who were not con-
sidered fit for intensive therapy, whereas the VALOR study
comprised R/R AML patients who had all previously
received intensive chemotherapy and were selected to
received additional intensive therapy in the R/R setting.
Additional trials are ongoing to determine the setting
and combination that best translates vosaroxin activity into
a clear survival benefit. Promising results have been pre-
sented from an ongoing phase I/II open-label, single-arm,
investigator-sponsored trial evaluating the safety and clin-
ical activity of vosaroxin in combination with decitabine in
patients C60 years of age with previously untreated AML
or high-risk myelodysplastic syndromes (MDS) [58]. This
trial consists of a lead-in phase I portion to determine a safe
dose of vosaroxin (using a starting dose of vosaroxin 90
mg/m2 IV on days 1 and 4) in combination with decitabine
20 mg/m2 IV on days 1-5, followed by a phase II
expansion. A total of 62 patients (55 with AML, seven with
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high-risk MDS) have been enrolled with a median patient
age of 69 years (range 60-78). Vosaroxin at the 90 mg/m2
dose level was well tolerated in the first six patients
enrolled in the phase I portion of the trial; however, eight
episodes of grade 3/4 mucositis occurred among the next
16 patients enrolled, and the vosaroxin dose was subse-
quently reduced to 70 mg/m2. Among all 62 enrolled
patients, the overall response rate (ORR) was 74 %,
including CR in 31 patients (50 %), with a median OS of
9.8 months. The reduction of the vosaroxin dose to 70
mg/m2 (n ¼ 40) from 90 mg/m2 (n ¼ 22) was associated
with reduced 8-week mortality (8 % with 70 mg/m2 vs. 23
% with 90 mg/m2), similar ORR (75 vs. 73 %, respec-
tively), and improved OS (median OS of 11.5 vs. 5.5
months, respectively). Therapy-related grade C3 toxicities
included mucositis in 11 patients (18 %) and liver enzyme
elevation in eight patients (13 %).
7 Conclusions and Clinical Impact
Vosaroxin is the first of a new class of anticancer agents and
is the first quinolone-based topoisomerase II inhibitor stud-
ied in clinical trials in cancer. Vosaroxin is a DNA interca-
lating topoisomerase II inhibitor that causes the induction of
apoptosis via double-strand DNA breaks; it is chemically
distinct from other topoisomerase inhibitors with a
stable quinolone-based core. Unlike etoposide, mitox-
antrone, and the anthracyclines, vosaroxin’s activity appears
to be exclusively attributable to intercalation and topoiso-
merase II inhibition, lacking cytotoxicity due to metabolic
activation and oxidative stress. The lack of significant toxic
metabolites, free radicals, and ROS may be the basis for the
low incidence of cardiac, pulmonary, renal, and hepatic
toxicities. Furthermore, vosaroxin demonstrates potent
in vitro antitumor activity in various tumor types including
those resistant to other topoisomerase II inhibitors.
In the pivotal phase III VALOR trial, a 2.1-month
improvement in OS among patients C60 years old was
demonstrated, with low early mortality. Common side
effects of vosaroxin included gastrointestinal effects,
myelosuppression, and infection. Vosaroxin may be an
effective therapeutic alternative for older AML patients,
those with treatment-resistant disease, and those who have
exceeded safe thresholds for anthracyclines or are at high
risk for treatment-related cardiac damage. Overall, vosar-
oxin represents a much needed novel treatment for patients
with R/R AML.
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